AR and breast cancer: Interestingly, many pre-clinical studies show differing proliferative versus anti-proliferative effects in ERα and AR-positive breast cancer that correlates with variation in the ratio of these steroid receptors and the availability of their respective ligands (i.e., estradiol and DHT).